{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T13:23:00Z","timestamp":1773667380664,"version":"3.50.1"},"reference-count":24,"publisher":"American Veterinary Medical Association (AVMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ajvr"],"published-print":{"date-parts":[[2007,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:p><jats:bold>Objective<\/jats:bold>\u2014To evaluate safety and efficacy of LDI-100, a preparation containing human chorionic gonadotropin (hCG) and bacillus Calmette-Guerin (BCG), in the treatment of dogs with mast cell tumors and to compare results with those from a control group receiving single-agent vinblastine.<\/jats:p>\n<jats:p><jats:bold>Animals<\/jats:bold>\u201495 dogs with measurable grade II or III mast cell tumors.<\/jats:p>\n<jats:p><jats:bold>Procedures<\/jats:bold>\u2014Dogs were randomized to receive either LDI-100 (1.35 ng of BCG and 2 units of hCG, SC, q 24 h) or vinblastine (2 mg\/m<jats:sup>2<\/jats:sup>, IV, q 1 wk) for 6 weeks. Tumors were measured at baseline and day 42, and dogs were monitored for signs of toxicosis. Clinical performance scores were recorded at each visit. Differences in host factors (sex, weight, and age), clinical performance score, tumor response, and adverse events were analyzed.<\/jats:p>\n<jats:p><jats:bold>Results<\/jats:bold>\u201446 dogs received LDI-100, and 49 dogs received vinblastine. No significant differences were found between the 2 treatment groups with regard to host factors or clinical performance score. Tumor response (\u226550% reduction) rates were similar between the LDI-100 and vinblastine group (28.6% and 11.7%, respectively). Dogs in the LDI-100 group had significantly less neutropenia than the vinblastine group.<\/jats:p>\n<jats:p><jats:bold>Conclusions and Clinical Relevance<\/jats:bold>\u2014hCG and BCG have immunomodulatory and antitumor effects against a variety of malignancies in humans and dogs. In this study, LDI-100 provided clinical responses comparable to single-agent vinblastine chemotherapy but without myelosuppression. LDI-100 is a promising new agent that should be further investigated for multimodality therapy of mast cell tumors in dogs.<\/jats:p>","DOI":"10.2460\/ajvr.68.11.1246","type":"journal-article","created":{"date-parts":[[2007,11,1]],"date-time":"2007-11-01T20:23:11Z","timestamp":1193948591000},"page":"1246-1251","source":"Crossref","is-referenced-by-count":28,"title":["Evaluation of a novel immunomodulator composed of human chorionic gonadotropin and bacillus Calmette-Guerin for treatment of canine mast cell tumors in clinically affected dogs"],"prefix":"10.2460","volume":"68","author":[{"given":"Carolyn J.","family":"Henry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sue","family":"Downing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert C.","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Kay","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karri","family":"Meleo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Armando","family":"Villamil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda S.","family":"Fineman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dudley L.","family":"McCaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Lynn","family":"Higginbotham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"McMichael","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1272","reference":[{"key":"ref1","series-title":"J Vet Intern Med","first-page":"491","article-title":"Prednisone and vinblastine chemotherapy for canine mast cell tumor\u201441 cases (1992\u20131997)","volume":"13","author":"Thamm","year":"1999"},{"key":"ref2","series-title":"J Am Anim Hosp Assoc","doi-asserted-by":"publisher","first-page":"124","DOI":"10.5326\/0400124","article-title":"Vinblastine and prednisone as adjunctive therapy for canine cutaneous mast cell tumors","volume":"40","author":"Davies","year":"2004"},{"key":"ref3","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/j.1939-1676.1999.tb02217.x","article-title":"Treatment of canine mast cell tumors with CCNU (Lomustine)","volume":"13","author":"Rassnick","year":"1999"},{"key":"ref4","series-title":"J Natl Cancer Inst","first-page":"789","article-title":"Biological response modifiers","volume":"70","author":"Oldham","year":"1983"},{"key":"ref5","series-title":"Urol Int","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1159\/000087163","article-title":"Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus Calmette-Guerin for superficial bladder tumors","volume":"75","author":"Eto","year":"2005"},{"key":"ref6","series-title":"Oncology","first-page":"719","article-title":"Intravesical therapy for superficial bladder cancer","volume":"14","author":"Baselli","year":"2000"},{"key":"ref7","series-title":"J Natl Cancer Inst","first-page":"1165","article-title":"Efficacy of intratumorally administered mycobacterial cell walls in the treatment of cattle with ocular carcinoma","volume":"67","author":"Kleinschuster","year":"1981"},{"key":"ref8","series-title":"J Am Vet Med Assoc","first-page":"269","article-title":"Immunotherapy of ocular equine sarcoid","volume":"174","author":"Murphy","year":"1979"},{"key":"ref9","series-title":"Ann N Y Acad Sci","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/j.1749-6632.1976.tb41681.x","article-title":"Immunotherapy of experimental cancer as guide to the treatment of human cancer","volume":"276","author":"Rapp","year":"1976"},{"key":"ref10","series-title":"Eur J Cancer","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/0014-2964(74)90133-9","article-title":"Effects of intravenous BCG in normal dogs and in dogs with spontaneous osteosarcoma","volume":"10","author":"Owen","year":"1974"},{"key":"ref11","series-title":"New Engl J Med","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1056\/NEJM199610243351702","article-title":"The effects of preparations of human chorionic goadotropin on AIDS-related Kaposi's sarcoma","volume":"335","author":"Gill","year":"1996"},{"key":"ref12","series-title":"J Natl Cancer Inst","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1093\/jnci\/89.23.1797","article-title":"Phase I study of human chorionic gonadotropin given subcutaneously to patients with acquired immunodeficiency syndrome-related mucocutaneous Kaposi's sarcoma","volume":"89","author":"Gill","year":"1997"},{"key":"ref13","series-title":"J Urol","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1097\/01.ju.0000084514.49252.64","article-title":"A trial study: the effect of low dose human chorionic gonadotropin on the symptoms of benign prostatic hyperplasia","volume":"170","author":"Godschalk","year":"2003"},{"key":"ref14","series-title":"Cancer Res","first-page":"3901","article-title":"Free human chorionic gonadotropin beta subunit in gonadal and nongonadal neoplasms","volume":"52","author":"Marcillac","year":"1992"},{"key":"ref15","series-title":"Cancer","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1002\/1097-0142(197610)38:4<1684::AID-CNCR2820380440>3.0.CO;2-T","article-title":"Human chorionic gonadotrophin (hCG) in nontrophoblastic neoplasms: assessment of abnormalities of hCG and DEA in bronchogenic and digestive neoplasms","volume":"38","author":"Gailani","year":"1976"},{"key":"ref16","series-title":"World J Gastroenterol","doi-asserted-by":"publisher","first-page":"7401","DOI":"10.3748\/wjg.v11.i47.7401","article-title":"Expression of human chorionic gonadotropin, CD44v6 and CD44v4\/5 in esophageal squamous cell carcinoma","volume":"11","author":"Li","year":"2005"},{"key":"ref17","series-title":"Leukemia","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1038\/sj.leu.2401196","article-title":"In vitro effects and clinical evaluation of a human chorionic gonadotrophin preparation in acute leukemia","volume":"12","author":"Feldman","year":"1998"},{"key":"ref18","series-title":"Vet Pathol","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1177\/030098588402100503","article-title":"Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs","volume":"21","author":"Patnaik","year":"1984"},{"key":"ref19","series-title":"J Natl Cancer Inst","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000"},{"key":"ref20","series-title":"Cancer","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L","article-title":"The use of nitrogen mustards in the palliative treatment of carcinoma","volume":"1","author":"Karnofsky","year":"1948"},{"key":"ref21","series-title":"Vet Comp Oncol","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/j.1476-5810.2004.0053a.x","article-title":"Veterinary Co-operative Oncology Group: consensus document","volume":"2","author":"Vail","year":"2004"},{"key":"ref22","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/j.1939-1676.1994.tb03259.x","article-title":"Response of canine mast cell tumors to treatment with oral prednisone","volume":"8","author":"McCaw","year":"1994"},{"key":"ref23","series-title":"Vet Q","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1080\/01652176.2004.9695178","article-title":"Mast cells and canine mast cell tumours. A review","volume":"26","author":"Misdorp","year":"2004"},{"key":"ref24","series-title":"Clin Cancer Res","first-page":"5729","article-title":"Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors","volume":"9","author":"Pryer","year":"2003"}],"container-title":["American Journal of Veterinary Research"],"original-title":[],"link":[{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/ajvr\/68\/11\/ajvr.68.11.1246.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/ajvr\/68\/11\/ajvr.68.11.1246.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/ajvr\/68\/11\/ajvr.68.11.1246.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T12:16:52Z","timestamp":1741349812000},"score":1,"resource":{"primary":{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/ajvr\/68\/11\/ajvr.68.11.1246.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11]]},"references-count":24,"journal-issue":{"issue":"11"},"URL":"https:\/\/doi.org\/10.2460\/ajvr.68.11.1246","relation":{},"ISSN":["0002-9645"],"issn-type":[{"value":"0002-9645","type":"print"}],"subject":[],"published":{"date-parts":[[2007,11]]}}}